Physician profile
Salman Farhat
NPI 1356780274
$8,080.04
in general payments reported to CMS, 2019-2025
16 companies · $3,684 in 2025
The $3,684 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $760 · 2022: $1,911 · 2023: $994 · 2024: $731 · 2025: $3,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,635 · Travel and Lodging: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,634.85 |
| Travel and Lodging | $1,774.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,870.96 | 2022-2025 | Xience Skypoint, Coroflow, Pressurewire |
| Abiomed | $1,550.91 | 2022-2025 | Impella |
| Penumbra, INC. | $1,533.05 | 2021-2025 | Indigo System, Penumbra System, Ruby Coil |
| Biotronik INC. | $1,195.44 | 2022 | |
| Inari Medical, INC. | $755.13 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shockwave Medical, INC | $313.02 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $282.08 | 2021-2022 | |
| Siemens Medical Solutions USA, INC. | $170.11 | 2021 | |
| Recor Medical INC | $118.41 | 2025 | Paradise Ultrasound Renal Denervation System |
| Boston Scientific Corporation | $94.07 | 2021 | |
| Acist Medical Systems, INC. | $71.74 | 2025 | |
| Terumo Medical Corporation | $49.41 | 2021 | |
| Asahi Intecc USA, INC. | $34.88 | 2022 | |
| Pfizer INC. | $27.20 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.63 | 2023 | Farxiga |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Farhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.